top of page
Our Approach
Our Approach
Our Approach
About Us
Latest news update:
Atorvia awarded inaugural Blue Ticket, sponsored by Merck, at new SpinUp lab at University of Toronto. Read more here.
Inhibiting cell death
Preserving organ function
Preventing kidney failure
Atorvia is pioneering treatments for organ failure, targeting the regulated cell death pathway that causes it.
Our primary goal is to prevent kidney failure and transform the way patients are treated by targeting the molecular causes of kidney damage, not the consequences of it.
We believe that being unique is powerful, and this applies as much to our people as it does to our science and strategy.
A proud recipient of the Ontario Bioscience Innovation Organization (OBIO) WiHI seed fund, supported by the Federal Economic Development Agency for Southern Ontario.
bottom of page